When medically appropriate, we prescribe GLP-1s for conditions like cardiac and vascular disease, sleep apnea, kidney disease, type 2 diabetes and stroke risk
Structurally, the product was optimized on the basis of exenatide, and the glycine 2, methionine 14 and asparagine 28 positions were modified to improve enzyme stability and chemical stability based on the polypeptide backbone
...and so much more
In the STEP 1 trial, semaglutide produced a mean weight reduction of about 14.9% at 68 weeks , with larger absolute reductions in some individuals
Specifically, GLP-1Rs on vagal afferent neurons have been shown to contribute to the incretin effects of GLP-1 shortly after a meal, gastric emptying, and glycemia (Krieger et al., 2015)
A well-established part of how they work is slowing gastric emptying, so food stays in the stomach longer, and this is documented in the FDA prescribing information for these drugs